Is Gossamer Bio, Inc. (GOSS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 175.1% / 30% | 254.1% / 30% | 4.6% / 30% | 1.55% / 5% | ✗ NOT HALAL |
| DJIM | 175.1% / 33% | 254.1% / 33% | 4.6% / 33% | 1.55% / 5% | ✗ NOT HALAL |
| MSCI | 64.3% / 33% | 93.4% / 33% | 1.7% / 33% | 1.55% / 5% | ✗ NOT HALAL |
| S&P | 175.1% / 33% | 254.1% / 33% | 4.6% / 33% | 1.55% / 5% | ✗ NOT HALAL |
| FTSE | 64.3% / 33% | 93.4% / 33% | 1.7% / 50% | 1.55% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 100.0% | |
| Operating Margin | -333.6% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -41.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$3M |
| Free Cash Flow | -$3M |
| Total Debt | $203M |
| Current Ratio | 2.6 |
| Total Assets | $315M |
Price & Trading
| Last Close | $0.37 |
| 50-Day MA | $1.44 |
| 200-Day MA | $2.18 |
| Avg Volume | 15.0M |
| Beta | 2.1 |
|
52-Week Range
$0.32
| |
About Gossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Gossamer Bio, Inc. (GOSS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Gossamer Bio, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Gossamer Bio, Inc.'s debt ratio?
Gossamer Bio, Inc.'s debt ratio is 175.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 64.3%.
What are Gossamer Bio, Inc.'s key financial metrics?
Gossamer Bio, Inc. has a market capitalization of $81M, and revenue of $115M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.